A detailed history of New York State Common Retirement Fund transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, New York State Common Retirement Fund holds 98,245 shares of BMRN stock, worth $6.51 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
98,245
Previous 299,579 67.21%
Holding current value
$6.51 Million
Previous $24.7 Million 72.0%
% of portfolio
0.01%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$69.02 - $93.84 $13.9 Million - $18.9 Million
-201,334 Reduced 67.21%
98,245 $6.91 Million
Q2 2024

Jul 31, 2024

BUY
$74.43 - $92.22 $188,307 - $233,316
2,530 Added 0.85%
299,579 $24.7 Million
Q1 2024

May 07, 2024

SELL
$83.81 - $99.0 $1.48 Million - $1.75 Million
-17,690 Reduced 5.62%
297,049 $25.9 Million
Q4 2023

Feb 01, 2024

SELL
$76.22 - $98.51 $1.26 Million - $1.63 Million
-16,537 Reduced 4.99%
314,739 $30.3 Million
Q3 2023

Nov 07, 2023

BUY
$85.07 - $94.48 $2.47 Million - $2.74 Million
29,043 Added 9.61%
331,276 $29.3 Million
Q2 2023

Aug 07, 2023

SELL
$86.68 - $100.3 $217,133 - $251,251
-2,505 Reduced 0.82%
302,233 $26.2 Million
Q1 2023

May 02, 2023

SELL
$87.74 - $117.27 $1.11 Million - $1.48 Million
-12,607 Reduced 3.97%
304,738 $29.6 Million
Q4 2022

Jan 30, 2023

SELL
$80.93 - $108.63 $5.25 Million - $7.05 Million
-64,922 Reduced 16.98%
317,345 $32.8 Million
Q3 2022

Nov 08, 2022

SELL
$82.16 - $96.94 $402,912 - $475,393
-4,904 Reduced 1.27%
382,267 $32.4 Million
Q2 2022

Aug 04, 2022

SELL
$71.48 - $86.85 $667,480 - $811,005
-9,338 Reduced 2.36%
387,171 $32.1 Million
Q1 2022

May 05, 2022

BUY
$74.28 - $92.69 $8.47 Million - $10.6 Million
114,048 Added 40.38%
396,509 $30.6 Million
Q4 2021

Feb 02, 2022

BUY
$71.72 - $91.47 $263,427 - $335,969
3,673 Added 1.32%
282,461 $25 Million
Q3 2021

Nov 02, 2021

SELL
$74.77 - $85.47 $10.8 Million - $12.4 Million
-144,826 Reduced 34.19%
278,788 $21.5 Million
Q2 2021

Aug 02, 2021

SELL
$75.51 - $84.79 $24,540 - $27,556
-325 Reduced 0.08%
423,614 $35.3 Million
Q1 2021

May 11, 2021

SELL
$74.73 - $90.69 $2.46 Million - $2.99 Million
-32,951 Reduced 7.21%
423,939 $32 Million
Q4 2020

Feb 08, 2021

SELL
$72.61 - $90.2 $2.13 Million - $2.65 Million
-29,400 Reduced 6.05%
456,890 $40.1 Million
Q3 2020

Nov 05, 2020

BUY
$71.87 - $131.03 $3.41 Million - $6.22 Million
47,487 Added 10.82%
486,290 $37 Million
Q2 2020

Aug 07, 2020

BUY
$79.55 - $124.22 $1.22 Million - $1.9 Million
15,316 Added 3.62%
438,803 $54.1 Million
Q1 2020

May 06, 2020

BUY
$71.37 - $96.85 $1.74 Million - $2.36 Million
24,398 Added 6.11%
423,487 $35.8 Million
Q4 2019

Feb 05, 2020

SELL
$64.27 - $86.37 $295,642 - $397,302
-4,600 Reduced 1.14%
399,089 $33.7 Million
Q3 2019

Nov 07, 2019

BUY
$67.4 - $85.11 $4.83 Million - $6.1 Million
71,689 Added 21.59%
403,689 $27.2 Million
Q2 2019

Aug 09, 2019

SELL
$80.35 - $93.9 $192,840 - $225,360
-2,400 Reduced 0.72%
332,000 $28.4 Million
Q1 2019

May 08, 2019

SELL
$84.2 - $98.62 $4.21 Million - $4.93 Million
-50,025 Reduced 13.01%
334,400 $29.7 Million
Q4 2018

Feb 08, 2019

SELL
$80.14 - $106.07 $7.29 Million - $9.65 Million
-90,990 Reduced 19.14%
384,425 $32.7 Million
Q2 2018

Aug 10, 2018

BUY
$76.01 - $99.03 $62,708 - $81,699
825 Added 0.17%
475,415 $44.8 Million
Q1 2018

May 10, 2018

SELL
$77.67 - $92.63 $776,700 - $926,300
-10,000 Reduced 2.06%
474,590 $38.5 Million
Q4 2017

Feb 13, 2018

SELL
$80.76 - $95.13 $96,912 - $114,156
-1,200 Reduced 0.25%
484,590 $43.2 Million
Q3 2017

Nov 06, 2017

BUY
$80.6 - $94.95 $564,200 - $664,650
7,000 Added 1.46%
485,790 $45.2 Million
Q2 2017

Aug 11, 2017

BUY
N/A
478,790
478,790 $43.5 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.